Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
In a phase 2 double‑blind randomized trial comparing psilocybin therapy with escitalopram for moderate‑to‑severe major depressive disorder, acute subjective experiences—particularly mystical experiences and ego dissolution—uniquely mediated the superior antidepressant response to psilocybin over a six‑week period. Emotional breakthrough and intense music‑evoked responses were also associated with greater symptom improvement, providing qualified support that acute psychological experiences may be causal mechanisms in psilocybin’s antidepressant effects.
Authors
- Robin Carhart-Harris
- David Nutt
- Leor Roseman
Published
Abstract
The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for the unique efficacy of PT versus Escitalopram Treatment over a core 6-week trial period. An exploratory-factor-analysis-derived single-factor of depression was used as the outcome. Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response. These results provide qualified support for the causal mechanistic role of acute psychological experiences in the treatment of depression via PT.
Research Summary of 'Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder'
Introduction
Weiss and colleagues situate their work within ongoing debates about how psychedelic therapies exert antidepressant effects, contrasting psychological models that emphasise acute subjective experiences (for example, mystical experience, emotional breakthrough, ego dissolution) with biologically centred accounts that prioritise neuroplastic processes linked to 5-HT2A receptor signalling. Earlier randomised and open-label studies have reported that mystical-type experiences and related phenomena correlate with clinical gains, but critics argue these experiences may be epiphenomenal to underlying biological change. The authors note evidence from neuroimaging and EEG that acute phenomenology covaries with brain-level changes (for example, decreased network modularity and increased signal complexity), supporting a biopsychosocial perspective in which psychological and physiological processes interact rather than one entirely subsuming the other. The present study uses data from a Phase II, double-blind, randomised comparator trial to test whether acute psychological experiences uniquely associated with Psilocybin Therapy (PT: two sessions of 25 mg psilocybin plus music and psychological support) versus Escitalopram Treatment (ET: two sessions of 1 mg psilocybin plus chronic escitalopram and psychological support) account for differences in depressive response over a 6-week core trial period. The investigation had three main aims: (1) test mediation by a broad set of acute experiences (including mystical experience, ego dissolution, emotional breakthrough, emotional insight/intensity, music impact, and challenging experiences) of the effect of treatment condition on an exploratory-factor-analytic “core” depression outcome; (2) test whether acute experiences moderated response within the PT arm; and (3) examine whether baseline trait absorption and suggestibility amplified any indirect effects. The authors frame the work as an exploratory but mechanistically focused attempt to parse psychological processes that might distinguish PT from conventional SSRI pharmacotherapy.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2024). Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder. International Journal of Mental Health and Addiction, 22(2), 806-841. https://doi.org/10.1007/s11469-024-01253-9
References (64)
Papers cited by this study that are also in Blossom
Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)
Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)
Agin-Liebes, G. I., Zeifman, R. J., Luoma, J. B. et al. · Journal of Psychopharmacology (2022)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Show all 64 referencesShow fewer
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)
Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)
Goodwin, G. M., Malievskaia, E., Fonzo, G. A. et al. · American Journal of Psychiatry (2023)
Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)
Hartogsohn, I. · Journal of Psychopharmacology (2016)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Kaelen, M., Barrett, F. S., Roseman, L. et al. · Psychopharmacology (2015)
Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)
Kangaslampi, S. · Journal of Psychedelic Studies (2023)
Karst, M., Halpern, J. H., Bernateck, M. et al. · Cephalalgia (2010)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Lii, T. R., Smith, A. E., Flohr, J. R. et al. · Nature Mental Health (2023)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)
Nayak, S., Singh, M., Yaden, D. B. et al. · Journal of Psychopharmacology (2022)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)
Shaw, L., Rea, K., Lachowsky, N. J. et al. · Journal of Psychoactive Drugs (2022)
Wall, M., Nutt, D. J., Kaelen, M. et al. · Journal of Psychopharmacology (2022)
Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Journal of Affective Disorders (2023)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Szigeti, B., Nutt, D. J., Carhart-Harris, R. L. et al. · Scientific Reports (2023)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Timmermann, C., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)
Cited By (6)
Papers in Blossom that reference this study
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W. et al. · Scientific Reports (2026)
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Brudner, R. M., Kaczmarek, E., Blainey, M. G. et al. · Journal of Psychopharmacology (2025)
Roseby, W., Kettner, H., Roseman, L. et al. · Frontiers in Psychology (2025)
Coleman, J. A., Shinozuka, K., Tromm, R. et al. · Human Brain Mapping (2025)
Silva, F., Butlen-Ducuing, F., Guizzaro, L. et al. · Neuroscience Applied (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.